SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper
Jaffray Healthcare Conference in New
York on Wednesday, December 3,
2014 at 1:00 p.m.
EDT/10:00 a.m. PDT. Dr.
Helen Torley, President and Chief
Executive Officer, will provide a corporate overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at www.halozyme.com, and a
recording will be made available for 90 days following the event.
To access the live webcast, please log on to Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a
biopharmaceutical company dedicated to developing and
commercializing innovative products that advance patient care. With
a diversified portfolio of enzymes that target the extracellular
matrix, the Company's research focuses primarily on a family of
human enzymes, known as hyaluronidases, which increase the
dispersion and absorption of biologics, drugs and fluids.
Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes and dermatology that have significant unmet
medical need today. The Company markets Hylenex®
recombinant (hyaluronidase human injection) and has
partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating,
please visit our corporate website at www.halozyme.com.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-piper-jaffray-healthcare-conference-300001172.html
SOURCE Halozyme Therapeutics, Inc.